Parsippany, New Jersey. Edenbridge Pharmaceuticals, LLC today announced that it has received final approval from the U.S. Food and Drug Administration on its Abbreviated New Drug Application for a generic version of Merck & Co., Inc.’s Stromectol®* (Ivermectin Tablets 3mg). Prior to today, there have been no FDA approved generic versions of Stromectol® and Edenbridge intends to begin shipping its Ivermectin Tablets USP 3mg product shortly. This is Edenbridge’s first FDA approval and one of several products filed by Edenbridge with the FDA over the last three years. Ivermectin is a semisynthetic, anthelmintic agent for oral administration. For more information please contact the Company directly at info@dexcelpharmausa.com.
Ivermectin Tablets, USP Approval
Specialty Products
To learn more about our specialty products, vigabatrin and Yargesa®, and how you may be able to save, please visit the Products page or navigate to a product-specific page.
Specialty Products
To learn more about our specialty products, vigabatrin and Yargesa®, and how you may be able to save, please visit the Products page or navigate to a product-specific page.